Litcius/Paper detail

Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial

Evangelos J. Giamarellos‐Bourboulis, Athanasios Siampanos, Amalia Bolanou, Sarantia Doulou, Nikolaos Kakavoulis, Konstantinos Tsiakos, Sokratis Katopodis, Georgios Schinas, Lamprini Skorda, Zoi Alexiou, Konstantinos Armenis, Paraskevi Κatsaounou, George Chrysos, Aikaterini Masgala, Garyphalia Poulakou, Nikolaos Antonakos, Asimina Safarika, Miltiades Kyprianou, Konstantina Dakou, Styliani Gerakari, Ιlias Papanikolaou, Haralampos Milionis, Markos Marangos, George Ν. Dalekos, Vasiliki Tzavara, Karolina Akinosoglou, Eryfilli Hatziaggelaki, Styliani Sympardi, Theano Kontopoulou, Maria Mouktaroudi, Antonios Papadopoulos, Michael S. Niederman

2024The Lancet Respiratory Medicine60 citationsDOI

Topics & Concepts

MedicineCommunity-acquired pneumoniaProcalcitoninInternal medicineClarithromycinPneumoniaPlaceboClinical endpointPopulationClinical trialSepsisHelicobacter pyloriPathologyEnvironmental healthAlternative medicinePneumonia and Respiratory InfectionsSepsis Diagnosis and TreatmentNosocomial Infections in ICU
Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial | Litcius